Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine

Vanessa Caceres  |  Issue: November 2016  |  November 16, 2016

Kelly Weselman, MD, FACR, WellStar Rheumatology, Smyrna, Ga., said the guidelines will likely result in some dosing adjustments for patients whose ideal and real body weight differ significantly.

Petros Efthimiou, MD, FACR, associate chief of rheumatology, New York Methodist Hospital, and associate professor of clinical medicine and rheumatology, Weill Medical College of Cornell University, New York, may ask patients to split tablets or use variable dosing by alternating or skipping doses on some days. “This way, hydroxychloroquine will be dosed according to the guidelines and retinal toxicity can be minimized, provided a careful ophthalmologic monitoring is also in place,” he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Some rheumatologists request that patients on HCQ and CQ get screened every year; the guidelines show that this is not usually necessary until five years of use. In fact, Dr. Weselman will change her recommendation for patients based on the update. “I will have some reassurance that such annual exams could be delayed until the patient has been maintained on the medication for five years,” she said.

All patients beginning long-term HCQ or CQ therapy should have a baseline eye exam in the first year of starting the drug.

Ophthalmologist Frederick W. Fraunfelder, MD, MBA, Roy E. Mason and Elizabeth Patee Mason Distinguished Professor, and chairman, ophthalmology, University of Missouri Health System, Columbia, focused on the value of making sure patients have a screening eye examination within the first year of treatment. “Any symptoms of visual loss or disturbance should be followed promptly by an ophthalmologist,” he said.

Dr. Efthimiou stressed the important role of HCQ and CQ for certain patients. “I want to emphasize how valuable antimalarial drugs are in the treatment of our diseases, especially SLE, where hydroxychloroquine is the cornerstone drug. While it is important to diagnose retinal toxicity, this has to be done carefully, using objective measures and confirmatory methods,” he said.

“Making a decision to stop this medication can present major problems for managing the underlying inflammatory disease,” Dr. Weselman said. However, she believes the guidelines strive for balance in stating the importance of the medications but also recommending further testing for verification of certain findings before making a decision to stop the medication.

Ophthalmologist Adrian W. Jachens, MD, EyeCare 20/20, East Hanover, N.J., applauded the fact that specific screening tools are recommended for annual screening. “SD-OCT is much more prevalent in ophthalmologists’ practices, so it makes sense to make it part of the required screening,” he said.

Based on the new guidelines, Dr. Jachens will ask patients using HCQ or CQ if they have any renal disease or have used tamoxifen, to help guide how often they should return after baseline screening.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 | Single Page
Share: 

Filed under:Conditions Tagged with:American Academy of OphthalmologychloroquineeyeguidelineHYDROXYCHLOROQUINEocularpatient carerecommendationretinopathyrheumatologistriskscreeningusagevision

Related Articles

    Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine

    November 16, 2016

    Both due to its efficacy and favorable side effect profile when compared with alternative drugs for rheumatologic conditions, hydroxychloroquine is an important agent in rheumatologists’ armamentarium. However, one barrier to hydroxychloroquine use can be its effects on the eye (also see “Revised Retinopathy Screening Guidelines,”). Ocular side effects of hydroxychloroquine can include impact on the…

    Hydroxychloroquine Retinopathy Still Alive and Well

    May 16, 2011

    How rheumatologists are affected by new guidelines from ophthalmology

    Stock Footage Inc / shutterstock.com

    ACR, Ophthalmologists & Dermatologists Issue Joint Hydroxychloroquine Statement

    April 17, 2021

    Since 1991, hydroxychloroquine (HCQ) has been a staple for the treatment of patients with systemic lupus erythematosus; it has been shown to improve survival, reduce cardiovascular risk, thrombosis and renal damage, delay or prevent lupus cerebritis and more. However, HCQ can potentially bind in the retinal pigment epithelium and cause degeneration of photoreceptors, leading to…

    nukeaf / shutterstock.com

    The History of Treating Lupus with Hydroxychloroquine

    June 15, 2020

    Given how unexpectedly front and center hydroxychloroquine has been in discussions about the treatment of COVID-19 this year, it makes sense to look at how it became so central to the treatment of a rheumatologic condition. In 1991, an article appeared in The New England Journal of Medicine that would alter the way rheumatologists approached…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences